I've listed some numbers from RM Research (reported in October 2007) for their 2009 forecast for Solagran earnings.
It's obvious that the numbers will be wrong due to subsequent events since the report such as the doubling of production of Ropren to 120,000 courses a year, Solagran and it's manufacturing partner, Galenopharm capturing 70% of the end consumer price for Ropren, SibEX from 60% to 85% ownership.
I'm just interested in what net profit is likely to be after deductions for Ropren in the coming year.
If we assume that it's priced at $1000 (just for the sake of calculation), and Solagran receive $120m in the coming year, what is likely to be left after deductions for distribution, manufacturing, royalties, taxes?
Anyone care to comment - cheers.
Profit and Loss statement 2009F
End user product sales revenue 75.6
Distributer & Pharmacy margin 19.7
Net Sales revenue 55.5
COS for manuf of Bioeffectives 14.0
Cost of manuf of end user products 3.4
Gross Profit 38.6
Total expenses less royalty 13.0
EBITDA 19.8
Depn & Amort 4.8
EBIT 15.0
Prima facie tax 4.5
Net profit 10.5
numbers from rm research
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)